MedTrace Logo

Safety, Tolerability and Therapeutic Efficacy of Topical ZEP-3 Ointment (1.0%) for the Treatment of Cold Sores

NCT02483182 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 210

Last updated 2019-05-30

No results posted yet for this study

Summary

This is a phase II, prospective, randomized, double-blind, parallel group, acyclovir-controlled clinical study to evaluate the safety, tolerability and preliminary therapeutic efficacy of ZEP-3 ointment 1.0% for the treatment of cold sores (Herpes labialis), following five consecutive treatment days with five times daily topical administration.

Conditions

  • Herpes Labialis

Interventions

DRUG

ZEP-3 ointment 1.0%

DRUG

Acyclovir cream 5%

Sponsors & Collaborators

  • Shulov Innovate for Science Ltd. 2012

    lead INDUSTRY

Principal Investigators

  • Shemer Avner, Prof., M.D. · Dermatology out-patients clinic, Lev Hayasmin - Medical center, Natanya, ISRAEL

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2018-06-24
Completion
2018-06-24

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02483182 on ClinicalTrials.gov